Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Treatment with subcutaneous toripalimab (JS001sc) plus chemotherapy exhibited noninferior drug exposure compared with toripalimab injection (JS001) for the frontline treatment of patients with metastatic or recurrent nonsquamous non–small cell…